Key result
Alteplase before CTA/CTP linked to a ~25-minute reduction in door-to-needle time versus contrast-first workflows.
Why the study?
Multimodal CTA/CTP is increasingly used in emergency department evaluations of acute ischemic stroke but may delay thrombolysis, leaving the effect of imaging sequencing on door-to-needle time unclear.
Does an alteplase-first workflow reduce door-to-needle time compared to a contrast-first workflow in adult patients with acute ischemic stroke?
Cohort (n=167)
No
Does an alteplase-first workflow reduce door-to-needle time compared to a contrast-first workflow in adult patients with acute ischemic stroke?
Mean Difference: -25 (95% CI -34–-16)
Absolute Event Rate: 20% vs 44%
p-value: p=<0.001
Administering intravenous alteplase before multimodal CTA/CTP imaging significantly reduces door-to-needle time by approximately 25 minutes in patients with acute ischemic stroke.
CTA/CTP before alteplase was associated with longer DTN times; leaves open optimal sequencing in AIS pending prospective confirmation.
Background and purpose Multimodal computed tomography angiography and perfusion (CTA/CTP) is increasingly used in the emergency department (ED) evaluation of acute ischemic stroke (AIS) but may delay thrombolysis. We examined whether the sequencing of multimodal CTA/CTP relative to thrombolytic administration affects door-to-needle (DTN) time. Methods We conducted a retrospective cohort study of adult patients with AIS treated with intravenous alteplase at a tertiary, academically affiliated ED that is part of a certified Comprehensive Stroke Center between January 1, 2012, and August 1, 2023. All patients underwent an initial noncontrast CT (NCCT), followed by either a contrast-first workflow (i.e. CTA/CTP) or were given alteplase before proceeding to contrast administration. The primary outcome was DTN time, analyzed using univariate methods and multivariable quantile regression adjusting for stroke severity, pre-alteplase antihypertensive use, thrombectomy (as a correlate for large-vessel occlusion), primary language, and bedside ED pharmacist presence. Results Among 1,382 AIS encounters, 167 patients met inclusion criteria; 148 underwent CTA/CTP before alteplase and 19 received alteplase before contrast administration. Median DTN time was significantly shorter in the alteplase-first group (20 minutes [interquartile range (IQR), 15–26]) compared with the CTA/CTP-first group (44 minutes [IQR, 32–56]; P<0.001). After adjustment, alteplase-first administration remained independently associated with faster DTN time (−25 minutes; 95% CI, −34 to −16). Higher stroke severity and ED pharmacist presence were also associated with shorter DTN, whereas pre-alteplase antihypertensives, primary language, and thrombectomy were not. Conclusions A contrast-first strategy incorporating multimodal CTA/CTP before alteplase administration was associated with approximately twofold longer DTN times. These findings suggest that obtaining CTA/CTP before thrombolytic administration may substantially prolong DTN times. Larger studies are needed to confirm the magnitude of this association and to identify patient populations most likely to benefit from alternative imaging workflows.
No takes yet. Share an insight, caveat, or question.
Coralic et al. (2026) conducted a cohort in Acute ischemic stroke (n=167). Alteplase administration before contrast imaging vs. Contrast imaging before alteplase administration was evaluated on Door-to-needle (DTN) time (MD -25 minutes, 95% CI -34 to -16, p=<0.001). Administering alteplase before multimodal CT angiography and perfusion imaging was independently associated with a 25-minute reduction in median door-to-needle time compared to a contrast-first strategy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: